Efficacy of Phlogenzyme® in men following transurethral laser enucleation of prostate hyperplasia: results of a randomized trial

Introduction. The most advanced and effective method of surgical treatment for benign prostatic hyperplasia (BPH) is transurethral laser enucleation of the prostate (tLEP). Recently, there has been a growing interest in exploring new approaches to reduce the risk of complications following tLEP.

Objective. To evaluate the efficacy of using Phlogenzym® as part of a comprehensive treatment plan for patients following tLEP to reduce dysuria (urinary discomfort), leukocyturia (white blood cells in urine), and prevent infectious and fibrosis-related complications.

Materials & methods. An open-label, randomized trial enrolled 105 patients undergoing tLEP. The patients were randomly assigned to two groups: the study group (n=50) received standard postoperative care in combination with Phlogenzym® for 30 days, while the control group (n=55) received standard care (α1-adrenergic blocker for 28 days) only. uring the follow-up period, which lasted for 1, 3, and 6 months postoperatively, complaints were evaluated using the IPSS-QoL, and IIEF-5 questionnaires, as well as indicators of urinalysis and urine culture, prostate volume measurements, residual urine volume, and uroflowmetry data.

Results. Among all patients, the median preoperative values for prostate volume, IPSS, QoL score, and median peak urine flow rate were 90 cc, 18 points, 5 points, and 7.9 mL/s, respectively, with no significant differences between the groups. One month after surgery, in the study group, there was a more significant decrease in prostate volume (57% vs. 41%), although this difference was not statistically significant (p > 0.05). At the 6-month follow-up, bacteriuria was less common in the study group (42% vs. 67%), and there was a consistent trend toward a reduction in the incidence of fibrous complications, although these differences were not statistically significant either (p > 0.05). No adverse events occurred during the follow-up period.

Conclusion. Our experience suggests that the use of Phlogenzym® is safe during the postoperative period following tLEP surgery. The use of this drug leads to a reduction in prostate volume postoperatively and significantly reduces the bacteriuria by the six-month follow-up. Additionally, there is a persistent positive trend towards reducing the overall incidence of fibrotic complications in the surgical site. The results achieved and the absence of significant side effects characterize Phlogenzym® as having a favorable clinical profile.

1. Zhang MW, El Tayeb MM, Borofsky MS, Dauw CA, Wagner KR, Lowry PS, Bird ET, Hudson TC, Lingeman JE. Comparison of Perioperative Outcomes Between Holmium Laser Enucleation of the Prostate and Robot-Assisted Simple Prostatectomy. J Endourol. 2017;31(9):847-850. DOI: 10.1089/end.2017.0095

2. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637-649. DOI: 10.1016/j.eururo.2003.08.015

3. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099-1109. DOI: 10.1016/j.eururo.2014.12.038

4. Oelke M, Kirschner-Hermanns R, Thiruchelvam N, Heesakkers J. Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011. Neurourol Urodyn. 2012;31(3):322-326. DOI: 10.1002/nau.22222

5. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246-249. DOI: 10.1016/j.juro.2008.03.058

6. Peshekhonov K.S., Shpilenia E.S., Komyakov B.K., Burlaka O.O., Sargsyan M.S. Endoscopic Treatment of Prostatic Hyperplasia in Elderly Patients: A Comparative Analysis of Resection and Enucleation Technique. Urology Herald. 2020;8(1):25-38. (In Russian). DOI: 10.21886/2308-6424-2020-8-1-25-38

7. Sun F, Sun X, Shi Q, Zhai Y. Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine (Baltimore). 2018;97(51):e13360. DOI: 10.1097/MD.0000000000013360

8. Zhong J, Feng Z, Peng Y, Liang H. A Systematic Review and Meta-analysis of Efficacy and Safety Following Holmium Laser Enucleation of Prostate and Transurethral Resection of Prostate for Benign Prostatic Hyperplasia. Urology. 2019;131:14-20. DOI: 10.1016/j.urology.2019.03.034

9. Lokshin K.L., Tangriberganov M.R., Gadzhieva Z.K. Sovremennye vozmozhnosti medikamentoznoj terapii pri sohranenii irritativnyh simptomov posle TUR DGPZh Effective pharmacotherapy. 2012;(39):24–27. (In Russian). eLIBRARY ID: 21853778; EDN: SKFWTF

10. Pushkar D.Y., Bernikov A.N., Khodyreva L.A., Dudareva A.A., Al'-Shukri S.K., Amdii R.E., Aboyan I.A., Shiranov K.A., Medvedev V.L., Efremov M.E. Quality of life in patients with lower urinary tract symptoms after TURP for benign prostatic hyperplasia. Urologiia. - 2018;(1):53-61. (In Russian). DOI: 10.18565/urology.2018.1.53-61

11. Wong L, Hutson PR, Bushman W. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate. 2015;75(1):23-32. DOI: 10.1002/pros.22886

12. Chen J, Dong W, Gao X, Li X, Cheng Z, Hai B, Pang Z. A systematic review and meta-analysis of efficacy and safety comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for patients with prostate volume less than 100 mL or 100 g. Transl Androl Urol. 2022;11(4):407-420. DOI: 10.21037/tau-21-1005

13. Park JK, Kim JY, You JH, Choi BR, Kam SC, Kim MK, Jeong YB, Shin YS. Effect of preoperative urethral dilatation on preventing urethral stricture after holmium laser enucleation of the prostate: A randomized controlled study. Can Urol Assoc J. 2019;13(11):E357-E360. DOI: 10.5489/cuaj.5781

14. Tascı AI, Ilbey YO, Tugcu V, Cicekler O, Cevik C, Zoroglu F. Transurethral resection of the prostate with monopolar resectoscope: single-surgeon experience and long-term results of after 3589 procedures. Urology. 2011;78(5):1151-1155. DOI: 10.1016/j.urology.2011.04.072

15. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)--incidence, management, and prevention. Eur Urol. 2006;50(5):969-979; discussion 980. DOI: 10.1016/j.eururo.2005.12.042

16. Kotov S.V., Bolotov A.D., Belomyttsev S.V., Surenkov D.N., Vorobyova A.V. Multicenter randomized study of bovhyaluronidase azoximer (Longidaza®) in men after transuretral resection of the prostate. Urologiia. 2021;(3):61-69. (In Russian). DOI: 10.18565/urology.2021.3.61-69

17. Kotov S.V., Guspanov R.I., Yusufov A.G., Semenov M.K., Abdulkhalygov E.Kh., Iritsyan M.M., Survillo I.I. Urethral Strictures after Transurethral Surgery: Treatment and Histological Issues. Creative surgery and oncology. 2020;10(1):10-15. (In Russian). DOI: 10.24060/2076-3093-2020-10-1-10-15

18. Burlev V.A., Dubinskaja E.D., Gasparov A.S. Peritoneal'nye spajki: ot patogeneza do profilaktiki. Problemy reprodukcii. 2009;15(3):36-44. (In Russian). eLIBRARY ID: 13418204; EDN: LHQKDR

19. Paradis ME, Couture P, Gigleux I, Marin J, Vohl MC, Lamarche B. Impact of systemic enzyme supplementation on low-grade inflammation in humans. PharmaNutrition. 2015;3(3):83-88. DOI: 10.1016/j.phanu.2015.04.004

20. Shatunova E.P., Lineva O.I., Kaganova M.A. Immune profile and treatment optimization in patients with chronic salpingo-oophoritis. Russian Bulletin of Obstetrician-Gynecologist. 2016;16(6):83-88. (In Russian). DOI: 10.17116/rosakush201616683-88

21. Adamyan L.V., Kozachenko A.V., Kondratovich L.M. Peritoneal adhesions: the history of researh, classification and pathogenesis (a review). Russian Journal of Human Reproduction. 2013;19(6):7 13. (In Russian). eLIBRARY ID: 21369797; EDN: RZQNGR

22. Minaev S.V. The use of enzyme preparations in pediatric abdominal surgery [dissertation]. St. Petersburg; 2004. (In Russian). Accessed April 09, 2024. https://medical-diss.com/docreader/248368/a?#?page=1

23. Burlev V.A. Pelvic peritoneum and peritoneal adhesions: inflammatory stress. Russian Journal of Human Reproduction. 2015;21(1):15-25. (In Russian). DOI: 10.17116/repro20152115-25

24. Lauer D, Müller R, Cott C, Otto A, Naumann M, Birkenmeier G. Modulation of growth factor binding properties of alpha2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol. 2001;47 Suppl:S4-9. DOI: 10.1007/s002800170002

25. Rapoport C. The use of trypsin in the therapy of tuberculous lymphadenitis and tuberculous fistulae. Dis Chest. 1958;34(2):154-161. PMID: 13561883

26. Tets V.V., Knorring G.Iu., Artemenko N.K., Zaslavskaia N.V., Artemenko K.L. Vliianie ékzogennikh proleoticheskikh fermentov na bakterii [Impact of exogenic proteolytic enzymes on bacteria]. Antibiot Khimioter. 2004;49(12):9-13. (In Russian). PMID: 16050494

27. Tkachuk V.N., Luk'janov A.Je. Mesto sistemnoj jenzimoterapii v kompleksnom lechenii bol'nyh hronicheski prostatitom. Vrachebnoe soslovie. 2007;(5):36-41. (In Russian).

28. Loran O.B., Pushkar' D.Yu., Segal AS., Judovskij S.O. Our understanding of chronic prostatitis. Farmateka. 2002; 10(61):69-76. (In Russian). eLIBRARY ID: 21925714; EDN: SLUUWX

29. Khryanin A.A. Microbial Biofilms: Modern Concepts. Antibiot Khimioter = Antibiotics and Chemotherapy. 2020;65(5-6):70-77. (In Russian). DOI: 10.37489/0235-2990-2020-65-5-6-70-77

30. Mikhailov I.B., Sternin Yu.I. Izbrannye voprosy klinicheskoi farmakologii sistemnoi enzimoterapii. The Russian Archives of Internal Medicine. 2012;(1):15-19. (In Russian). DOI: 10.20514/2226-6704-2012-0-1-15-19